Skip to main content
TipRanks
Go Ultimate75% OFF

Elite Pharmaceuticals (ELTP) Stock Statistics & Valuation Metrics

378 Followers

Total Valuation

Elite Pharmaceuticals has a market cap or net worth of $349.02M. The enterprise value is $242.02M.

Market Cap
$349.02M
Enterprise Value
$242.02M

Share Statistics

Elite Pharmaceuticals has 1,077,569,800 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
1,077,569,800
Owned by Insiders
0.87%
Owned by Institutions
<0.01%

Financial Efficiency

Elite Pharmaceuticals’s return on equity (ROE) is 0.45 and return on invested capital (ROIC) is 32.33%.

Return on Equity (ROE)
0.45
Return on Assets (ROA)
0.32
Return on Invested Capital (ROIC)
32.33%
Return on Capital Employed (ROCE)
0.41
Revenue Per Employee
2.29M
Profits Per Employee
690.35K
Employee Count
65
Asset Turnover
1.08
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Elite Pharmaceuticals is 5.68. Elite Pharmaceuticals’s PEG ratio is 0.01.

PE Ratio
5.68
PS Ratio
2.37
PB Ratio
2.81
Price to FCF
39.35
Price to Operating Cash Flow
31.58
PEG Ratio
0.01

Income Statement

In the last 12 months, Elite Pharmaceuticals had revenue of 148.87M and earned 44.87M in profits. Earnings per share was 0.04.

Revenue
148.87M
Gross Profit
73.48M
Operating Income
49.96M
Pretax Income
56.81M
Net Income
44.87M
EBITDA
51.98M
Earnings Per Share (EPS)
0.04

Cash Flow

In the last 12 months, operating cash flow was 10.86M and capital expenditures -2.15M, giving a free cash flow of 8.72M billion.

Operating Cash Flow
10.86M
Free Cash Flow
8.72M
Free Cash Flow per Share
0.01

Dividends & Yields

Elite Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
2.51%
Earnings Yield
17.38%

Stock Price Statistics

Beta
1.51
52-Week Price Change
-44.12%
50-Day Moving Average
0.25
200-Day Moving Average
0.34
Relative Strength Index (RSI)
62.96
Average Volume (3m)
836.61K

Important Dates

Elite Pharmaceuticals upcoming earnings date is Feb 16, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 12, 2026
Next Earnings Date
Feb 16, 2027
Ex-Dividend Date
―

Financial Position

Elite Pharmaceuticals as a current ratio of 6.45, with Debt / Equity ratio of 5.88%

Current Ratio
6.45
Quick Ratio
-1215.99
Debt to Market Cap
0.01
Net Debt to EBITDA
-573.16
Interest Coverage Ratio
125.95

Taxes

In the past 12 months, Elite Pharmaceuticals has paid 11.94M in taxes.

Income Tax
11.94M
Effective Tax Rate
0.21

Enterprise Valuation

Elite Pharmaceuticals EV to EBITDA ratio is 8.03, with an EV/FCF ratio of 36.38.

EV to Sales
2.19
EV to EBITDA
8.03
EV to Free Cash Flow
36.38
EV to Operating Cash Flow
29.20

Balance Sheet

Elite Pharmaceuticals has $34.86M in cash and marketable securities with $5.18M in debt, giving a net cash position of $29.68M billion.

Cash & Marketable Securities
$34.86M
Total Debt
$5.18M
Net Cash
$29.68M
Net Cash Per Share
$0.03
Tangible Book Value Per Share
$0.11

Margins

Gross margin is 43.41%, with operating margin of 25.90%, and net profit margin of 41.64%.

Gross Margin
43.41%
Operating Margin
25.90%
Pretax Margin
47.76%
Net Profit Margin
41.64%
EBITDA Margin
27.29%
EBIT Margin
25.90%

Analyst Forecast

The average price target for Elite Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
17.81%
EPS Growth Forecast
331.54%

Scores

Smart Score
4
AI Score
77